Briggs Morrison - Jun 5, 2025 Form 3/A - Amendment Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Director
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Jun 5, 2025
Transactions value $
$0
Form type
3/A - Amendment
Date filed
6/10/2025, 05:31 PM
Date Of Original Report
Jun 6, 2025
Previous filing
Jun 27, 2024
Next filing
Jun 13, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Morrison Briggs Director C/O CRIPSR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON /s/ Elizabeth Ryland Waldinger, attorney-in-fact 2025-06-10 0001654430

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CRSP Common Shares 5.21K Jun 5, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CRSP Stock Option (Right to Buy) Jun 5, 2025 Common Shares 26K $48.68 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Form 3 filed on June 6, 2025 for the Reporting Person reported an incorrect number of shares held by the Reporting Person as of June 5, 2025. This amended Form 3 is being filed to correct such number of shares held by the Reporting Person as of June 5, 2025.
F2 This option was granted on December 10, 2024 with respect to 26,000 Common Shares. 100% of the shares will vest in 36 equal monthly installments, with the first vesting date of January 10, 2025.

Remarks:

This amendment is being filed solely to correct the reporting of ownership of certain Common Shares reported in Table I. See Footnote 1 hereto.